Location: FH 1-2

## WER Wilson Sonsini Goodrich & Rosati

## RECEIVED CENTRAL FAX CENTER

OCT 2 0 2005

Date: October 20, 2005 Use this fax To: Examiner Janet L. Epps Ford Fax: 571-273-0757 number only ☐ Notify recipient Company: U.S. Patent and Trademark Office Phone: before sending Phone: 650-849-3383 Return Fax: 650-493-6811 From: Eric Witt ☑ Original will not follow Original: To follow via mail ☐ To follow via courier To follow via email Fax Contains: 2 pages (including this sheet). If incomplete, call [insert your direct number]. Re: Application No.: 09/211,794; Flied: December 15, 1998 ; Group Art Unit: 1635, Examiner Janet L. Epps Ford Message: **Dear Examiner Epps-Ford** Attached please find the Terminal Disclaimer that we discussed in our telephone conversation of Tuesday, October 18, 2005. Please let me know if there is anything else that you need. My direct dial number is 650-565-3546. Respectfully. Eric Witt Reg. No. 44,408

650 Page Mill Road, Palo Alto, CA 94304-1050 • 650.493.9300 Tel • 650.493.6811 Fax • www.wsgr.com

Return Original to: Cathy Bachmann/Eric Witt

This fax may contain confidential and privileged material for the sole use of the intended recipient. Any review or distribution by others is strictly prohibited.

If you are not the intended recipient please contact the sender and destroy all copies.

Entire Transmission Copyright @ 2003 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.

Ref: 31249-710.301

## RECEIVED CENTRAL FAX CENTER

No.0667 P. 2

OCT 2 0 2005

PTO/SB/26 (09-04)

Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TERMINAL DISCLAIMER TO OBVIATE PATENTING REJECTION OVER A "PRIOR" PATENT

Docket Number (Optional) 31249-710.301

In re Application of: Amy Arrow, et al.

Application No.: 09/211,794 Filed: December 15, 1998

For: Three Component Chimeric Antisense Oligonucleotides

The owner', Ollgos Etc., Inc., Invitrogen Corporation, and Sirna Therapeutics, Inc., of 100 percent Interest in the instant application here by disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term prior patent No. 5,989,912 issued on November 23, 1999) as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the Instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later:

expires for fallure to pay a maintenance fee;

is held unenforceable;

is found invalid by a court of competent jurisdiction;

is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;

has all claims canceled by a reexamination certificate;

is reissuad: or

is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal discialmer.

Check either box 1 or 2 below, if appropriate.

For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the Ilke so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent Issued thereon.

The undersigned is an attorney or agent of record.

Date: October 20, 2005

650 Page Mill Road Palo Alto, CA 94304 (650) 493-9300

(650) 493-9300 Telephone Number

Terminal disclaimer fee under 37 CFR 1.20(d) included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

\*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. 1450, Alexandris, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandris, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.